Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 9, Issue 3, 2008, Pages 163-175

  Dietz, Rainer ^a   Dechend, Ralf ^b   Yu, Chuek Man ^c   Bheda, Manesh ^d   Ford, Jessica ^d   Prescott, Margaret F ^d   Keefe, Deborah L ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FRANZ VOLHARD CLINIC   (Germany)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Aliskiren; Beta blocker; Plasma renin activity; Pulse pressure; Renin angiotensin system

Indexed keywords

ALISKIREN; ATENOLOL; RENIN;

ADULT; ARTICLE; ASTHENIA; BACKACHE; BLOOD PRESSURE REGULATION; BRADYCARDIA; BRAIN HEMORRHAGE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CHINA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROENTERITIS; GERMANY; HEADACHE; HUMAN; HYPERTENSION; INDIA; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; RHINOPHARYNGITIS; SIDE EFFECT; SITTING; SOUTH AFRICA; SPAIN; SUPRAVENTRICULAR TACHYCARDIA; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME; TURKEY (REPUBLIC); UREA BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; AMIDES; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; DEMOGRAPHY; DIASTOLE; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; FUMARATES; HEART RATE; HUMANS; HYPERTENSION; MALE; RENIN; RENIN-ANGIOTENSIN SYSTEM; SYSTOLE;

EID: 56749085787     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/1470320308096411     Document Type: Article

References (43)

1. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl 2005;23:S9-S17.
2. Wood JM, Maibaum J, Rahuel J et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308:698-705.
3. Nussherger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39:E1-E8.
4. Pool JL, Schmieder RE, Azizi M et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20:11-20.
5. Uresin Y, Taylor A, Kilo C et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8: 190-8.
6. Villamil A, Chrysant SG, Calhoun D et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25:217-26.
7. Kilo C, Taylor A, Tschope D, Ibram G, Fang H, Prescott MF. Aliskiren, a novel renin inhibitor for treatment of hypertension, enhances renin system suppression by reducing plasma renin activity alone or in combination with ramipril in patients with diabetes. Eur Heart J 2006;27(suppl):118-19 P789.
8. Yarows SA, Oparil S, Patel S, Zhang J, Fang H, Satlin A. Suppression of the renin system with the oral direct renin inhibitor aliskiren alone and in combination with valsartan in patients with hypertension. J Hypertens 2007, 25(suppl):S257-S258
9. Nielsen I, Steiness E, Hesse B. Acute and long-term salt depletion and beta-blockade: plasma renin activity response and its relation to blood pressure reduction in long-term treatment. Acta Med Scand 1978; 203:415-18.
10. Bravo EL, Tarazi RC, Dustan HP, Lewis JW. Dissociation between renin and arterial pressure responses to beta-adrenergic blockade in human essential hypertension. Circ Res 1975;36:241-7.
11. Blumenfeld JD, Sealey JE, Mann SJ et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 1999;12:451-9.
12. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18:139-85.
13. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
14. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53.
15. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006; 174:1737-42.
16. Wiysonge C, Bradley H, Mayosi B et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007;CD002003.
17. National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care. 2006; http://www,nice.org.uk/CG034 accessed 28th March 2007.
18. Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotensin Aldosterone Syst 2006;7:61-3.
19. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.
20. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004; 17:1-7.
21. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. JAMA 1982;248:2004-11.
22. Psaty BM, Furberg CD, Kuller LH et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. Arch Intern Med 2001;161:1183-92.
23. Vaccarino V, Holford TR, Krumholz HM. Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol 2000;36:130-8.
24. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 1999;100: 354-60.
25. Blacher J, Staessen JA, Girerd X et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000;160:1085-9.
26. Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery? J Hypertens 2005;23:551-6.
27. Chen CH, Ting CT, Lin SJ et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension 1995;25:1034-41.
28. Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-25.
29. Buhler FR, Laragh JH, Baer L, Vaughan ED Jr, Brunner HR. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 1972;287:1209-14.
30. Nilsson OR, Karlberg BE, Ohlsson O, Thulin T, Tolagen K. Atenolol administered once daily in primary hypertension. Effects on blood pressure in relation to pre-treatment plasma renin activity. Acta Med Scand 1979;206:303-8.
31. Michelakis AM, McAllister RG. The effect of chronic adrenergic receptor blockade on plasma renin activity in man. J Clin Endocrinol Metab 1972;34:386-94.
32. Bravo EL, Tarazi RC, Dustan HP. On the mechanism of suppressed plasma-renin activity during beta-adrenergic blockade with propranolol. J Lab Clin Med 1974;83:119-28.
33. Lijnen P, Fagard R, Staessen J, Amery A. Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension. Br J Clin Pharmacol 1981;12:387-92.
34. Batenburg WW, de Bruin RJ, van Gool JM et al. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008; 28:1151-7.
35. Menard J, Guyene TT, Peyrard S, Azizi M. Conformational changes in prorenin during renin inhibition in vitro and in vivo. J Hypertens 2006;24:529-34.
36. Schalekamp MA, Derkx FH, Deinum J, Danser AJ. Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors. J Hypertens 2008;26:928-37.
37. Mason JM, Dickinson HO, Nicolson DJ, Campbell F, Ford GA, Williams B. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens 2005; 23:1777-81.
38. Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005; 28:2261-6.
39. Weycker D, Edelsberg J, Vincze G et al. Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. J Hum Hypertens 2007; 21:374-80.
40. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49: 1157-63.
41. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-18.
42. Sica D, Gradman AH, Lederballe O, Meyers M, Cai J, Keefe DL. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Eur Heart J 2006;27(suppl):121 P797.
43. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326: 1427-34.